Imatinib mesylate, also known as STI571 or Glivec (Novartis, Basel, Switzerland), is a promising new treatment for chronic myelogenous leukemia (CML). Imatinib mesylate is a 2-phenylaminopyrimidine derivate that was designed as a selective competitive inhibitor of the Abl protein tyrosine kinases (v-Abl, Bcr-Abl, and c-Abl). [1] [2] [3] [4][5] It also has strong activity against the platelet-derived growth-factor receptor (PDGF-R), c-Kit, ARG, and their fusion proteins Tel-Abl and Tel-PDGF-R, but does not affect other kinases. [6][7][8][9] Recent clinical trials of imatinib mesylate in the treatment of chronic-phase CML have demonstrated that the drug is well tolerated with only few adverse effects and can induce complete hematologic and cytogenetic responses in a significant proportion of patients. 2, 3, [10][11][12] Moreover, activity of imatinib mesylate against more advanced, accelerated-phase blast crises and in patients with relapsed or refractory Philadelphia chromosomepositive (Ph ϩ ) acute lymphoid leukemias was reported. 13, 14 Furthermore, in patients with gastrointestinal stroma tumors (GISTs), where activating mutations of c-Kit are likely responsible for the pathogenetic events, imatinib mesylate yielded encouraging results. 6,7, 15, 16 Because this tumor has so far been highly refractory to chemotherapy, imatinib mesylate is emerging as an important new therapeutic agent.
Introduction
Imatinib mesylate, also known as STI571 or Glivec (Novartis, Basel, Switzerland), is a promising new treatment for chronic myelogenous leukemia (CML). Imatinib mesylate is a 2-phenylaminopyrimidine derivate that was designed as a selective competitive inhibitor of the Abl protein tyrosine kinases (v-Abl, Bcr-Abl, and c-Abl). [1] [2] [3] [4] [5] It also has strong activity against the platelet-derived growth-factor receptor (PDGF-R), c-Kit, ARG, and their fusion proteins Tel-Abl and Tel-PDGF-R, but does not affect other kinases. [6] [7] [8] [9] Recent clinical trials of imatinib mesylate in the treatment of chronic-phase CML have demonstrated that the drug is well tolerated with only few adverse effects and can induce complete hematologic and cytogenetic responses in a significant proportion of patients. 2, 3, [10] [11] [12] Moreover, activity of imatinib mesylate against more advanced, accelerated-phase blast crises and in patients with relapsed or refractory Philadelphia chromosomepositive (Ph ϩ ) acute lymphoid leukemias was reported. 13, 14 Furthermore, in patients with gastrointestinal stroma tumors (GISTs), where activating mutations of c-Kit are likely responsible for the pathogenetic events, imatinib mesylate yielded encouraging results. 6, 7, 15, 16 Because this tumor has so far been highly refractory to chemotherapy, imatinib mesylate is emerging as an important new therapeutic agent.
However, the effects of imatinib mesylate on normal, nonmalignant hematopoietic cells have not been extensively evaluated so far. It is not clear whether some side effects like cytopenias that occur during treatment with imatinib mesylate may result from suppression of normal progenitor growth and differentiation. Recently, it was demonstrated that imatinib mesylate reduces the number of colony-forming cells in peripheral blood or bone marrow (BM) from patients with CML, with minimal effect on normal cells. 17 Dendritic cells (DCs) are recognized as the most powerful antigenpresenting cells (APCs) with the unique ability to initiate and maintain primary immune responses. They originate from BM-derived progenitor cells, spread via the bloodstream, and can be found in almost every organ as the sentinels of the immune system. In vitro, DCs can be generated from peripheral blood monocytes using granulocytemacrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). The differentiation of DCs from CD34 ϩ progenitor cells can be mediated by different cytokines like GM-CSF, tumor necrosis factor ␣ (TNF-␣), IL-4, and FMS-like tyrosine kinase 3 (FLT3) ligand and stem cell factor (SCF). [18] [19] [20] [21] [22] [23] [24] [25] Because SCF has been shown to play an important role in DC development, we here explored a potential effect of imatinib mesylate on the development of mobilized human CD34 ϩ peripheral blood progenitor cells (PBPCs) into DCs. We show that in vitro exposure of CD34 ϩ PBPCs to therapeutic concentrations of imatinib mesylate (1-5 M) affects the differentiation and functional properties of generated DCs via inhibition of the nuclear factor B (NF-B) family member RelB.
Materials and methods

Cells and reagents
All cells were cultured in RPMI 1640 with glutamax-I, supplemented with 10% inactivated fetal calf serum (FCS), 50 M 2-mercaptoethanol, and antibiotics (Invitrogen, Karlsruhe, Germany). Imatinib mesylate was a kind gift of Novartis Pharmaceuticals (Basel, Switzerland). The cell lines used in the experiments were A498 (renal cell carcinoma cell line, Her-2/neu ϩ , HLA-A2 ϩ ; DSMZ, Braunschweig, Germany), Croft (Epstein-Barr virus [EBV]-immortalized B-cell line, Her-2/neu Ϫ , HLA-A2 ϩ , kindly provided by O. J. Finn, Pittsburgh, PA), SK-OV-3 (ovary adenocarcinoma cell line, HLA-A3 ϩ , kindly provided by O. J. Finn). The CML cell line K562 was used to determine the activity of natural killer (NK) cells.
DC generation
DCs were generated from human CD34 ϩ PBPCs mobilized with granulocyte colony-stimulating factor (G-CSF) as described previously. 26 In brief, cryopreserved CD34 ϩ cells were cultured for 10 to 16 days with a combination of different cytokines (GM-CSF [100 ng/mL; Leucomax, Novartis], IL-4 [20 ng/mL; R&D Systems, Wiesbaden, Germany), TNF-␣ [10 ng/mL; R&D Systems], and FLT3 ligand [FLT3L; 100 ng/mL; R&D Systems]). Cytokines were added to differentiating DCs every 2 to 3 days. Imatinib mesylate was dissolved in dimethyl sulfoxide (DMSO) and added to the culture medium starting from the first day of culture together with GM-CSF, IL-4, TNF-␣, and FLT3L in concentrations varying from 1 to 5 M. Equal amounts of DMSO were added to the control cells to exclude any effects of the solvent. In some experiments, DC maturation was induced by adding soluble CD40 ligand (CD40L, 500 ng/mL; Bender MedSystems, Vienna, Austria) and interferon ␥ (IFN-␥; 100 U/mL; R&D Systems) 24 hours before harvesting the cells. For blocking experiments, monoclonal antibodies against SCF (1 g/mL; R&D Systems) and its receptor c-Kit (10 g/mL; Sigma, Deisenhofen, Germany) were added to the cells together with the cytokines. Mouse IgG (Dianova, Hamburg, Germany) was added to control cells. DCs were enumerated by flow cytometry as lineage (CD14, CD3, CD19) negative and HLA-DR bright. Furthermore, analysis of the expression levels of the DC markers CD1a and CD83 and costimulatory molecules CD80, CD86, and CD40 was performed.
Immunostaining
Cells were stained using fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated mouse monoclonal antibodies against CD14, CD80, HLA-DR, CD3, CD19, CD54, CD11c (Becton Dickinson, Heidelberg, Germany); CD40, CD86, CD33 (PharMingen, Hamburg, Germany); CD1a, CD11a (Dako Diagnostika, Hamburg, Germany); CD83 (Immunotech, Marseille, France); and mouse IgG isotype control (Becton Dickinson). Cells were analyzed on a FACSCalibur cytometer (Becton Dickinson). To calculate the percentage of positive cells, a proportion of 1% false-positive events was accepted in the negative control samples throughout.
Detection of apoptosis
For detection of apoptosis, the annexin V-Fluos staining kit (Roche Diagnostics, Mannheim, Germany) was used according to the instructions of the manufacturer. In addition, leakage of fragmented DNA from apoptotic nuclei was measured as described previously. 27, 28 In short, DC nuclei were isolated using a hypotonic lysis buffer (0.1% sodium citrate, 0.1% Triton X-100, 50 mg/mL propidium iodide) and immediately analyzed by flow cytometry.
Induction of antigen-specific CTL responses
The induction of Her-2/neu and influenza matrix protein (IMP)-specific CTL was performed as described previously. [29] [30] [31] The HLA-A2-binding peptides derived from Her-2/neu E75 (amino acids 369-377: KIGSFLAFL), IMP peptide (amino acids 58-66: GILGFVFTL), and HIV (pol HIV-1 reverse transcriptase peptide; amino acids 476-484: ILKEPVHGV) were synthesized using standard F-moc chemistry on a peptide synthesizer (432A; Applied Biosystems, Weiterstadt, Germany) and analyzed by reversed-phase high-performance liquid chromatography and mass spectrometry. For induction of peptide-specific cytotoxic T lymphocytes (CTLs), 5 ϫ 10 5 DCs were pulsed with 50 g/mL E75 or IMP peptide for 2 hours, washed, and incubated with 3 ϫ 10 6 peripheral blood mononuclear cells (PBMNCs) without imatinib mesylate. After 7 days of culture, cells were restimulated with autologous peptide-pulsed PBMNCs, and 2 ng/mL IL-2 (R&D Systems) was added on days 1, 3, and 5. The cytolytic activity of induced CTLs was analyzed on day 5 after the last restimulation in a standard 51 Cr-release assay.
CTL assay
The standard 51 Cr-release assay was performed as described previously. [29] [30] [31] Target cells were pulsed with 50 g/mL peptide for 2 hours and labeled with [ 51 Cr]-sodium chromate for 1 hour at 37°C. Then, 1 ϫ 10 4 cells were transferred to a well of a round-bottom 96-well plate. Varying numbers of CTLs were added to a final volume of 200 L and incubated for 4 hours at 37°C. At the end of the assay, supernatants (50 L/well) were harvested and counted in a ␤-plate counter. The percentage of specific lysis was calculated as: 100 ϫ (experimental release Ϫ spontaneous release/maximal release Ϫ spontaneous release). Spontaneous and maximal releases were determined in the presence of either medium or 2% Triton X-100, respectively.
For antibody-blocking experiments, cells were incubated for 30 minutes with 10 g/mL monoclonal antibody BB7.2 against HLA-A2 (kindly provided by Stefan Stevanovic, Tübingen, Germany) and mouse IgG, respectively, before seeding in 96-well plates.
RT-PCR
Reverse transcription-polymerase chain reaction (RT-PCR) was performed with some modifications as described previously. 32, 33 Total RNA (800 ng) was subjected to cDNA synthesis. Numbers of PCR cycles performed were 25 for macrophage inflammatory protein 1␣ (MIP-1␣), ELC, and RelB, and 22 for CCR7.
Preparation of nuclear extracts
Nuclear extracts were prepared from DCs as described previously. 34 The homogenate was centrifuged for 30 seconds in a microfuge and the supernatant containing cytoplasmatic proteins was transferred to a new tube. The nuclear pellet was resuspended in 50 L ice-cold buffer C (20 mM HEPES, pH 7.9; 0.4 M NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM DTT; 1 mM PMSF) and incubated on ice for 15 minutes with vigorous shaking every 2 to 3 minutes. After 5 minutes of centrifugation, the supernatants were stored at Ϫ80°C.
Polyacrylamide gel electrophoresis and Western blotting
Protein concentrations of nuclear extracts were determined using a bicinchoninic acid (BCA) assay (Pierce, Perbio Science, Bonn, Germany). Approximately 20 g nuclear extracts were separated by 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany). The blot was probed with a polyclonal rabbit RelB antibody (C-19; Santa Cruz Biotechnology, Santa Cruz, CA), a monoclonal mouse c-Rel antibody (B-6; Santa Cruz Biotechnology), or a polyclonal rabbit RelA antibody (Upstate Biotechnology, Lake Placid, NY) followed by incubation with a horseradish peroxidase-conjugated secondary antibody. Bands were visualized by enhanced chemiluminescence (ECL) staining (Amersham Biosciences Europe, Freiburg, Germany).
Results
Exposure of mobilized CD34 ؉ PBPCs to imatinib mesylate inhibits their differentiation into DCs
SCF and its receptor were shown to play a critical role during the development of DCs from CD34 ϩ progenitor cells. [19] [20] [21] 23, 24 Because imatinib mesylate is a selective inhibitor of the Abl tyrosine kinases with equipotent activity against PDGF-R and c-Kitassociated tyrosine kinases, 1, 6, 8, 9 we determined the effect of imatinib mesylate on the normal development of DCs by monitoring the acquisition of DC morphology and phenotype after 10 to 16 days in culture. Purified human CD34 ϩ PBPCs from healthy donors mobilized with G-CSF were cultured with GM-CSF and TNF-␣. 18 The cells differentiated into large, round, loosely adherent cells showing the typical cell protrusions in the form of veils or dendrites. Phenotypic analysis of GM-CSF/TNF-␣-generated DCs demonstrated acquisition of a DC phenotype characterized by the expression of CD1a, CD83, HLA-DR, and costimulatory molecules such as CD80, CD86, and CD40. Addition of 1.25 M imatinib mesylate together with GM-CSF and TNF-␣ from the first day of culture did not substantially affect the morphology but severely altered DC phenotype, characterized by reduction of CD1a, CD83, HLA-DR, CD80, and CD40 expression ( Figure 1A ), while not affecting CD86 and CD54 levels.
In the next set of experiments we evaluated whether the inhibitory effects of imatinib mesylate can be antagonized using a different cytokine combination including the ligand of the receptor tyrosine kinase FLT3. However, cells cultured in the presence of GM-CSF, TNF-␣, IL-4, and FLT3L together with 1.25 M imatinib mesylate demonstrated a similar phenotype as the one observed in previous experiments ( Figure 1B) .
Moreover, the inhibitory effects of imatinib mesylate were found to be concentration dependent, as monitored by evaluating cell phenotypes after incubation with different imatinib mesylate concentrations (1 M, 3 M, 5 M; Figure 1C ), whereas no differences in the expression of CD33, CD11a, and CD11c were detected (data not shown). Importantly, the observed effects of imatinib mesylate were not mediated by the induction of cell death. When checking the viability of the cell populations and rate of apoptosis induction by annexin V and propidium iodide cell staining, we did not detect any increase in the rate of dead cells following exposure to the compound ( Figure 2 ). These results were further confirmed by analyzing the leakage of fragmented DNA from apoptotic nuclei as described by Nicoletti et al 27 (data not shown).
To determine the possible role of c-Kit in the observed inhibition of DC development, we incubated CD34 ϩ cells with blocking antibodies against SCF and its receptor c-Kit. However, no effect on DC development could be detected (Figure 3 ), indicating that imatinib mesylate acts by inhibition of other tyrosine kinases.
To further evaluate the responsiveness of DCs generated in the presence of imatinib mesylate to a maturation stimulus, we added soluble CD40L and IFN-␥ 24 hours before harvesting the cells. As shown in Figure 4 , the inhibitory effects of imatinib mesylate on DC surface expression of CD1a, CD83, CD80, and CD40 could not be antagonized by these maturation stimuli.
Exposure to imatinib mesylate reduces the capacity of DCs to activate lymphocyte responses
Initiation of primary immune responses is a unique feature of DCs. We therefore analyzed the ability of the DCs generated from CD34 ϩ progenitor cells in the presence of GM-CSF, TNF-␣, IL-4, and FLT-3L with or without imatinib mesylate to induce antigenspecific T cells against the Her-2/neu antigen. For the induction of a primary CTL response, DCs generated from CD34 ϩ cells were pulsed with the synthetic HLA-A2-binding peptide E75 derived from Her-2/neu tumor-associated antigen and used as APCs. After For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From 2 weekly restimulations, the CTL lines showed peptide-specific and HLA-A2-restricted killing of tumor cell lines pulsed with the cognate peptide or constitutively expressing the Her-2/neu antigen ( Figure 5A ). DCs generated in the presence of 3 M imatinib mesylate failed to activate antigen-specific CTL responses ( Figure  5B ). Similar results were observed when a recall antigen (IMP peptide) was used for the induction of antigen-specific CTLs. CTL lines generated with DCs grown with GM-CSF/TNF-␣/IL-4/ FLT3L showed peptide-specific killing of tumor cell lines pulsed with the IMP peptide ( Figure 5C ), whereas DCs generated in the presence of 3 M imatinib mesylate were unable to elicit a CTL response ( Figure 5D ).
The inhibitory effects of imatinib mesylate on the stimulatory capacity of DCs were not due to an increased secretion of IL-10 as analyzed by a commercially available enzyme-linked immunosorbent assay (data not shown).
Imatinib mesylate modulates chemokine mRNA level in DCs
Transcription of chemokines known to be important for DC function was analyzed by RT-PCR. On treatment with imatinib mesylate in different concentrations, mRNA level of MIP-1␣ was up-regulated ( Figure 6 ), whereas no differences in the transcription of TARC (CCL17) and the chemokine receptor CCR6 were observed (data not shown). In contrast, mRNA levels of ELC (CCL19) and the corresponding receptor CCR7 were reduced in the presence of imatinib mesylate (Figure 6 ).
Imatinib mesylate down-regulates nuclear RelB transcription factor but not c-Rel and RelA
Recently it was shown that members of the NF-B family of transcription factors are important for the differentiation and function of DCs. [35] [36] [37] [38] [39] [40] [41] Because we did not detect any effect of imatinib mesylate on the level of RelB mRNA expression by RT-PCR (Figure 6 ), we further evaluated the nuclear localization of RelB, RelA, and c-Rel proteins in the generated DC populations. As shown in Figure 7 , Western blot analysis revealed that the amount of nuclear-localized RelB and its induction by maturation stimuli is reduced in DCs generated in the presence of 3 M imatinib mesylate, whereas the expression of RelA and c-Rel proteins was not affected. These results suggest that the effects of imatinib mesylate are mediated at least in part by inhibition of NF-B signaling pathways.
Discussion
The causative event in the initiation of CML is the formation of the Bcr-Abl oncogene, which codes for a constitutively activated tyrosine kinase as a result of the reciprocal translocation t(9;22). Therefore, a specific inhibitor of the Bcr-Abl kinase was thought to be effective in the therapy of patients with CML.
Imatinib mesylate is an adenosine triphosphate (ATP)-competitive inhibitor of the Abl tyrosine kinases (v-Abl, Bcr-Abl, c-Abl) [1] [2] [3] [4] and was also shown to inhibit c-Kit, ARG, PDGF-R, and their fusion proteins, but has no significant activity against other kinases. 1, 3, 42, 43 Moreover, in vitro studies revealed that the antiproliferative activity of imatinib mesylate occurred only in cells that expressed activated forms of Abl (Bcr-Abl, Tel-Abl, v-Abl, c-Abl), mutated forms of c-Kit, and activated PDGF-R (Tel-PDGF-R, v-sis-activated PDGF-R). 3, 6, 9, 44, 45 In recent clinical trials, the tyrosine kinase inhibitor imatinib mesylate has shown promising results in the treatment of CML and also demonstrated activity in patients with myeloproliferative disorders including activating mutations in the gene encoding PDGF-R␤ 46 as well as in patients with GISTs involving activating mutations of the c-Kit gene. 6, 7, 15, 16 Recently, it could be demonstrated that imatinib mesylate inhibits the proliferation of CML primitive precursors rather than to For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From induce apoptosis, resulting in removal of the proliferative advantage of Bcr-Abl progenitors but not in elimination of these cells. 47 In addition, it was shown that nondividing, quiescent Ph ϩ hematopoietic stem cells are insensitive to imatinib mesylate in vitro. 48 In contrast to Ph ϩ hematopoiesis, little is known about the effect of imatinib mesylate on growth and differentiation of normal, nonmalignant hematopoietic stem and progenitor as well as differentiated cells. Previous studies revealed that imatinib mesylate reduces the number of colony-forming cells in peripheral blood or BM from patients with CML while not affecting normal hematopoiesis 17 and has no significant effects on hematopoietic recovery in mice in vivo. 49 Here we demonstrate that imatinib mesylate can directly act on mobilized human CD34 ϩ progenitor cells and inhibits their differentiation into DCs. This finding might be of major clinical importance because imatinib mesylate is given continuously so far to prevent disease relapse. Furthermore, because CML in particular is considered to be an "immunogenic" disease, an impaired immune response due to treatment-related side effects could alter the immune surveillance by the organism, thereby potentially impairing immune-mediated long-term disease control. Recent data emphasize this aspect by showing that treatment of patients with the immune stimulatory cytokine IFN-␣ led to up-regulation of myeloblastin (MBN) expression and to detection of MBNspecific CTL in all patients studied. In contrast, in only a minority of patients treated with imatinib mesylate were MBN-specific CTLs detected. 50 DCs are professional APCs that are important for the initiation of primary immune responses. 51 They acquire antigens in the periphery that they process to peptide fragments and present in the context of major histocompatibility complex (MHC) molecules. On activation, they migrate to secondary lymphoid organs where the peptide-MHC complexes are presented to and recognized by antigen-specific T lymphocytes via the T-cell receptor. [51] [52] [53] DCs residing in tissues originate from BM-derived circulating precursors that home in peripheral tissues and are able to further develop into antigen-capturing DCs. 51, 52 It was shown that CD34 ϩ progenitor cells can be induced to differentiate into DCs in vitro using different cytokine combinations, including SCF. 18, 19, 23, 54 We therefore analyzed the effect of imatinib mesylate on the differentiation and function of DCs generated ex vivo from human CD34 ϩ PBPCs that were mobilized with G-CSF.
The presence of imatinib mesylate in cell cultures in concentrations varying from 1 to 5 M, serum levels typically achieved in patients, resulted in a severely altered DC phenotype characterized by reduction of DC surface markers CD1a and CD83 and costimulatory molecules CD80 and CD40 in a concentrationdependent manner. These effects were not mediated by induction of apoptosis, because the analysis of cell viability, which was examined by annexin V and propidium iodide staining, did not reveal a higher rate of apoptosis induction in the cell culture in the presence of imatinib mesylate.
In the next set of experiments we analyzed the possible effects of different cytokine combinations including FLT3L on the inhibition of DC differentiation by imatinib mesylate. FLT3L is an important growth and differentiation factor for DCs and was shown to expand different DC populations in vitro and in vivo in mice and humans. [55] [56] [57] [58] FLT3L is the ligand for the FLT3 that is a member of the PDGF-R tyrosine kinase subfamily and shares the structural features of KIT, FMS, and PDGF-R. 59 On binding, FLT3L induces dimerization of the receptor leading to the activation of the tyrosine kinase domain, which results in autophosphorylation. Downstream signaling proteins of FLT3 include RAS-GAP, PLC-␥, PI3K, STAT5, and ERK1/2. This signal transduction pathway of FLT3L converges with the pathway of c-Kit activation. In our experiments, however, the use of a cytokine combination containing GM-CSF, TNF-␣, IL-4, and FLT3L could not antagonize the inhibiting effects mediated by imatinib mesylate.
Interestingly, we could not mimic the changes in the DC phenotype observed on the incubation of cells with imatinib mesylate using blocking antibodies specific for SCF and c-Kit, because culturing CD34 ϩ PBPCs in the presence of these antibodies resulted in a normal DC phenotype suggesting that other mechanisms might be active and are not mediated by inhibition of c-Kit receptor signaling.
In line with the altered DC phenotype we found that the capacity of DCs generated in the presence of imatinib mesylate to induce antigen-specific T-cell responses against tumor-associated antigens (Her-2/neu) or a recall antigen (IMP), was impaired. This effect was most likely due to the decreased expression of costimulatory molecules including CD80 and CD40. This inhibition was not mediated by IL-10, which was shown to be immunosuppressive by inhibition of antigen presentation in APCs and induction of T-cell tolerance. [60] [61] [62] [63] The Rel/NF-B proteins p50, p52, p65, c-Rel, and RelB constitute a family of transcription factors involved in the regulation of a variety of genes during the immune response. [35] [36] [37] [38] [39] [40] [41] NF-B activation occurs by nuclear translocation caused by the inducible phosphorylation of inhibiting IB proteins by the IB kinase complex. Targeted disruption of RelB gene in mice as well as in in vitro studies revealed that it plays a critical role in DC function and differentiation. RelB Ϫ/Ϫ mice produce no apparent mature myeloid DCs, 41 and BM chimeras have shown that it is due to a direct effect of RelB on stem cell development. 39 We therefore analyzed the expression of RelB by RT-PCR and Western blot analysis in cells generated in the presence of imatinib mesylate. Whereas the mRNA level of RelB was not affected by imatinib mesylate, the nuclear-localized RelB protein was downregulated in DCs treated with imatinib mesylate and could not be induced on maturation with CD40L and IFN-␥. In contrast, expression of RelA and c-Rel was not affected. These results suggest that the effects of imatinib mesylate are mediated at least in part via inhibition of RelB signaling, and therefore represent a novel signal transduction way of imatinib mesylate. 
